nyuuzyou/wikis huggingface dataset:
Sorafenib Dosing Nomogram

Last updated on 2024-07-23:TBA regimens on this page
TBA variants on this page
=AAML1031 Sorafenib Dosing Nomogram=
Note: BSA is rounded to the hundredth place.
BSA Range (m2) 	Dose Level 0 (100 mg/m2/day once daily)	Dose Level 1 (200 mg/m2/day once daily)	Dose Level 2 (300 mg/m2/day divided twice per day)
Less than or equal to 0.35	50 mg x 4 days/week,
0 x 3 day/week
(200 mg)	50 mg x 5 days/week,
100 mg x 2 days/week
(450 mg)	50 mg twice per day x 7 days/week
(700 mg)
0.36 to 0.40 	50 mg x 5 days/week,
0 x 2 day/week
(250 mg)	50 mg x 4 days/week,
100 mg x 3 days/week
(500 mg)	50 mg twice per day x 6 days/week +
100 mg twice per day x 1 day/week
(800 mg)
0.41 to 0.45 	50 mg x 6 days/week,
0 x 1 day/week
(300 mg)	50 mg x 2 days/week,
100 mg x 5 days/week
(600 mg)	50 mg twice per day x 5 days/week +
100 mg twice per day x 2 days/week
(900 mg)
0.46 to 0.55 	50 mg x 7 days/week
(350 mg) 	100 mg x 7 days/week
(700 mg) 	50 mg q AM +100 mg q PM
x 7 days/week
(1050 mg)
0.56 to 0.60 	50 mg x 6 days/week,
100 mg x 1 day/week
(400 mg)	100 mg x 6 days/week,
200 mg x 1 day/week
(800 mg)	50 mg twice per day x 2 days/week +
100 mg twice per day x 5 days/week
(1200 mg)
0.61 to 0.70 	50 mg x 5 days/week,
100 mg x 2 days/week
(450 mg)	100 mg x 5 days/week,
200 x 2 days/week
(900 mg)	100 mg twice per day x 7 days/week
(1400 mg)
0.71 to 0.80 	50 mg x4 days/week,
100 mg x3 days/week
(500 mg)	150 mg x 7 days/week
(1050mg) 	100 mg twice per day x 5 days/week +
150 mg twice per day x 2 days/week
(1600 mg)
0.81 to 0.90 	50 mg x 2 days/week,
100 mg x 5 days/week
(600 mg)	150 mg x 4 days/week,
200 mg x 3
days/week
(1200 mg)	100 mg q AM + 150 mg q PM
x 7 days/week
(1750 mg)
0.91 to 1.05 	100 mg x 7 days/week
(700 mg) 	200 mg x 7 days/week
(1400 mg) 	150 mg twice per day x 7 days/week
(2100 mg)
1.06 to 1.20 	100 mg x 6 days/week,
200 mg x1 day/week
(800 mg)	200
mg x 3 days/week,
250 mg x 4 days/week
(1600 mg)	150 mg q AM + 200 mg q PM
x 7 days/week
(2450 mg)
1.21 to 1.35 	100 mg x 5 days/week,
200 mg x 2 days/week
(900 mg)	250 mg x 7 days/week
(1750 mg) 	200 mg twice per day x 7 days/week
(2800 mg)
1.36 to 1.60 	100 mg x 4 days/week,
200 mg x 3 days/week
(1000 mg)	300 mg x 7 days/week
(2100 mg) 	200 mg q AM + 250 mg q PM
x 7 days/week
(3150 mg)
1.61 to 1.70 	100 mg x 2 days/week,
200 mg x 5 days/week
(1200 mg)	350 mg x 7 days/week
(2450 mg) 	250 mg twice per day x 7
days/week
(3500 mg)
1.71 to 1.85 	100 mg x 1 day/week,
200 mg x 6 days/week
(1300 mg)	350 mg x 3 days/week
400 mg x 4 days/week
(2650 mg)	250 mg q AM + 300 mg q PM
x 7 days/week
(3850 mg)
1.86 or more 	200 mg x 7 days/week
(1400 mg) 	400 mg x 7 days/week
(2800 mg) 	300 mg twice per day x 7 days /week
(4200 mg)
Category:General reference pages
Category:Clinical pharmacology
Sotorasib (Lumakras)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available agent that targets the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. 
==Diseases for which it is established==
*Colorectal cancer, KRAS-mutated
*Non-small cell lung cancer, KRAS-mutated
==Diseases for which it is used==
*Pancreatic cancer
==History of changes in FDA indication==
*2021-05-28: Accelerated approval for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. (Based on CodeBreaK100NSCLC)
*2025-01-16: Approved with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Based on CodeBreaK 300)
==History of changes in EMA indication==
*2022-01-06: Initial conditional authorization as Lumykras.
==History of changes in Health Canada indication==
*2021-09-10: Initial notice of compliance with conditions for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
==History of changes in PMDA indication==
*2022-01-20: Newly indicated for the treatment of unresectable advanced or recurrent KRAS G12C mutation-positive non-small cell lung cancer that has progressed after cancer chemotherapy.
==Also known as==
*Code name: AMG-510
*Brand name: Lumakras, Lumykras
Category:Drugs
Category:Oral medications
Category:KRAS inhibitors
Category:Mutation-specific medications
Category:Colorectal cancer medications
Category:Non-small cell lung cancer medications
Category:Pancreatic cancer medications
Category:FDA approved in 2021
Category:Health Canada approved in 2021
Category:EMA approved in 2022
Category:PMDA approved in 2022
Sources

Knowledge aggregation sites such as HemOnc.org could not exist without primary sources. We access primary sources through a variety of means, including subscription to eTOCs, conference proceedings, and customized e-mail alerts through EuroPMC and other sources. This is a list of the sources that we use most frequently; decisions on whether to include treatment regimens are informed by our eligibility criteria.
="Top-tier" general medical journals=
*JAMA
*The Lancet
*The New England Journal of Medicine
="Top-tier" hematology/oncology journals=
*Annals of Oncology Official journal of the European Society for Medical Oncology (ESMO)
*Blood Official journal of the American Society of Hematology (ASH)
*JAMA Oncology
*Journal of Clinical Oncology Official journal of the American Society of Clinical Oncology (ASCO)
*The Lancet Haematology
*The Lancet Oncology
=Other hematology/oncology journals=
*Blood Advances
*British Journal of Haematology Official journal of the British Society for Haematology
*Cancer Published on behalf of the American Cancer Society (ACS)
*Clinical Cancer Research
*Clinical Lymphoma, Myeloma & Leukemia
*Haematologica Journal of the European Hematology Association (EHA)
*Journal of Hematology & Oncology Official journal of the Chinese American Hematologist and Oncologist Network
*Journal of the National Cancer Institute
*Lancet Gastroenterology and Hepatology
*Lancet Neurology
*Leukemia
*Leukemia & Lymphoma
*Seminars in Oncology
=Conference proceedings=
*ASCO Annual Meeting Proceedings
*ASH Annual Meeting Abstracts
*EHA Abstract Book
*ESMO Scientific Meeting Reports
=E-mail Alerts=
*ASH Practice Updates
*FDA Oncology Drug Approvals
*Research to Practice
Category:Evidence-based oncology
Sovleplenib (HMPL-523)

==Mechanism of action==
Spleen tyrosine kinase (SYK) inhibitor
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Immune thrombocytopenia===
# ESLIM-01: Hu Y, Liu X, Zhou H, Wang S, Huang R, Wang Y, Du X, Sun J, Zhou Z, Yan Z, Chen W, Wang W, Liu Q, Zeng Q, Gong Y, Yin J, Shen X, Ye B, Chen Y, Xu Y, Sun H, Cheng Y, Liu Z, Wang C, Yuan G, Zhang X, Li X, Cheng P, Guo X, Jiang Z, Yang F, Yang L, Luo C, Xiao T, Fu S, Yin H, Guo X, Xu Q, Fan S, Shi MM, Su W, Mei H, Yang R. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024 Aug;11(8):e567-e579. Epub 2024 Jun 14. link to original article EuroPMC NCT05029635
==Also known as==
*Code name: HMPL-523
Category:Drugs
Category:Oral medications
Category:SYK inhibitors
Category:Immune thrombocytopenia medications (investigational)
Category:Investigational drugs
St Elizabeth's Medical Center Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
==Basic information==
Name: St. Elizabeth's Medical Center Hematology Oncology Fellowship
Fellowship program website: https://www.semc.org/31/content/hematology-oncology-fellowship
ACGME ID: 1552421124
===Leadership===
*Program Director: 
===Fellowship Coordinator===
==Application process and requirements==
https://www.semc.org/31/content/hematology-oncology-fellowship
===Process===
*Applications accepted starting on: 
*Application deadline: 
*Applications submitted through ERAS
===Requirements===
*Applications will not be processsed until letters of recommendation and USMLE scores are received
*USMLE Step I and II
*Three letters of recommendation, one must be from Program Director
*Personal Statement
*US Citizen, US Permanent Resident; H-1B visa is possible
==Statistics==
*Number of fellowship positions available per year: 
*Board certification eligibility upon fellowship completion: Hematology and Oncology 
*Length of fellowship: 3 years
==Schedule==
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*St Elizabeth's Medical Center
*Dana-Farber Cancer Institute
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Steroid conversions

Steroid 	Equivalent (glucocorticoid) dose (mg)	Half-life (hours), biologic	Relative anti-inflammatory (glucocorticoid) potency	Relative mineralocorticoid (Na+ retaining) potency
Cortisone 	25 	8-12 	0.8 	0.8
Hydrocortisone (Cortef) 	20 	8-12 	1 	1
Prednisone (Sterapred) 	5 	18-36 	4 	0.8
Prednisolone (Millipred) 	5 	18-36 	4 	0.8
Methylprednisolone (Solumedrol)	4 	18-36 	5 	0.5
Dexamethasone (Decadron) 	0.75 	36-54 	25 	0
==References==
# Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977 Aug;63(2):200-7. EuroPMC
Category:General reference pages
Category:Clinical pharmacology
Streptozocin (Zanosar)

==General information==
Class/mechanism: Nitrosourea, alkylates DNA and RNA, antibiotic oncologic, mechanism not fully understood. Streptozocin has been observed to have greater toxicity to pancreatic islet beta cells, possibly because streptozocin can be transported into beta cells via the glucose transport protein GLUT2.Streptozocin (Zanosar) package insertStreptozocin (Zanosar) package insert (locally hosted backup)Zanosar manufacturer's website
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
*Adrenocortical carcinoma
*Neuroendocrine tumor
*Pancreatic NET
==Diseases for which it was used==
*Hodgkin lymphoma
*Pancreatic cancer
==Patient drug information==
*Streptozocin (Zanosar) patient drug information from manufacturerStreptozocin (Zanosar) patient information from manufacturer
*Streptozocin (Zanosar) patient drug information (Chemocare)Streptozocin (Zanosar) patient drug information (Chemocare)
*Streptozocin (Zanosar) patient drug information (UpToDate)Streptozocin (Zanosar) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1982-05-07: Initial FDA approval for the treatment of metastatic islet cell carcinoma of the pancreas. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease. (No supporting studies are cited)
==History of changes in EMA indication==
*1982-05-07: EURD
==History of changes in PMDA indication==
*2014-09-26: Initial approval for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract.
==Also known as==
*Generic name: STZ
*Brand name: Zanosar
==References==
Category:Drugs
Category:Intravenous medications
Category:Alkylating agents
Category:Nitrosoureas
Category:Adrenocortical carcinoma medications
Category:Neuroendocrine tumor medications
Category:Pancreatic NET medications
Category:Classical Hodgkin lymphoma medications (historic)
Category:Pancreatic cancer medications (historic)
Category:FDA approved in 1982
Category:EMA approved in 1982
Category:PMDA approved in 2014
Strontium-89 (Metastron)

==General information==
Radioactive strontium
==Diseases for which it was used==
*Prostate cancer
==History of changes in FDA indication==
*1993-06-18: Initial approval for the relief of bone pain in patients with painful skeletal metastases.
==History of changes in PMDA indication==
*2007-07-31: Initial approval for pain relief in bone scintigraphy-positive metastatic lesions in patients with solid cancers.
==Also known as==
*Brand name: Metastron
Category:Drugs
Category:Radiotherapy medications
Category:Intravenous medications
Category:Prostate cancer medications
Category:FDA approved in 1993
Category:PMDA approved in 2007
Category:Stub
Subependymal giant cell astrocytoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main SEGA page for regimens that include active anticancer treatment.
=All lines of therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Franz et al. 2012 (EXIST-1)	2009-2013 	Phase 3 (C)	Everolimus	Lower confirmed response rate (primary endpoint)
No active antineoplastic treatment.
===References===
# EXIST-1: Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013 Jan 12;381(9861):125-32. Epub 2012 Nov 14. Erratum in: Lancet. 2013 Jan 12;381(9861):116. link to original article EuroPMC NCT00789828
##Update: Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014 Dec;15(13):1513-1520. Epub 2014 Nov 10. link to original article EuroPMC
##Update: Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Niolat J, Jóźwiak S. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS One. 2016 Jun 28;11(6):e0158476. link to original article link to PMC article EuroPMC
Category:Subependymal giant cell astrocytoma regimens
Category:Disease-specific pages
Category:Low-grade gliomas
Category:Null regimens
Sugemalimab (Cejemly)

==General information==
Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Toxicity management==
*Immunotherapy toxicity management
==Diseases for which it is used==
*Non-small cell lung cancer
**Non-small cell lung cancer, nonsquamous
**Non-small cell lung cancer, squamous
==History of changes in NMPA indication==
*2022-06-06: Approved for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy. (Based on GEMSTONE-301)
==Also known as==
*Brand name: Cejemly
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-L1 antibodies
Category:Non-small cell lung cancer medications
Category:Non-small cell lung cancer, nonsquamous medications
Category:Non-small cell lung cancer, squamous medications
Category:NMPA approved in 2022
Suramin (Antrypol)

==Mechanism of action==
Antiparasitic with mechanism of action unclear.
==Diseases for which it was used==
*Prostate cancer
==History of changes in FDA indication==
*This drug is not FDA approved. Of note, it was investigated in prostate cancer but utility was not proven and investigations have been discontinued.
==Also known as==
*Brand name: Antrypol
Category:Drugs
Category:Intravenous medications
Category:Antiparasitic
Category:WHO Essential Anti-infective Medicines
Category:Prostate cancer medications (historic)
Category:Stub
Sutimlimab (Enjaymo)

==Mechanism of action==
Anti-C1s antibody
==Diseases for which it is used==
*Cold agglutinin disease
==History of changes in FDA indication==
*2022-02-04: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)
==History of changes in EMA indication==
*2022-11-15: Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
==History of changes in PMDA indication==
*2022-06-20: A drug with a new active ingredient indicated for the treatment of cold agglutinin disease.
==Also known as==
*Code name: BIVV-009
*Generic name: sutimlimab-jome
*Brand name: Enjaymo
 
Category:Drugs
Category:Intravenous medications
Category:Anti-C1s antibodies
Category:Cold agglutinin disease medications
Category:EMA approved in 2022
Category:FDA approved in 2022
Category:PMDA approved in 2022
Synovial sarcoma

Back to Top
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
Last updated on 2024-11-20:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
=Advanced or metastatic disease, subsequent lines of therapy=
==Afamitresgene autoleucel monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence
D'Angelo et al. 2024 (SPEARHEAD-1)	2019-12-17 to 2021-07-27	Phase 2 (RT)
====Preceding treatment====
*Lymphodepletion with FC
====Targeted therapy====
*Afamitresgene autoleucel (Tecelra) 1 x 109 to 10 x 109 T cells IV once on day 0
One course
===References===
#SPEARHEAD-1: D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13;403(10435):1460-1471. Epub 2024 Mar 27. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT04044768
Category:Synovial sarcoma regimens
Category:Disease-specific pages
Category:Soft tissue sarcomas
Systemic mastocytosis - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main systemic mastocytosis page for regimens that include active anticancer treatment.
=All lines of therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Lortholary et al. 2017 (AB06006)	2009-2015 	Phase 3 (C) 	Masitinib 	Lower cumulative response
Gotlib et al. 2023 (PIONEER) 	2020-09 to 2022-01 	Randomized Phase 2 (C)	Avapritinib	Worse mean change in total symptom score
No active antineoplastic treatment.
===References===
# AB06006: Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017 Feb 11;389(10069):612-620. Epub 2017 Jan 6. link to original article link to PMC article EuroPMC NCT00814073
#PIONEER: Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023 Jun;2(6):EVIDoa2200339. Epub 2023 May 23. link to original article EuroPMC NCT03731260
Category:Systemic mastocytosis regimens
Category:Disease-specific pages
Category:Myeloproliferative neoplasms
Category:Null regimens
T-cell lymphoma

=T-cell lymphoma regimens have been moved to their histology-specific subtype pages. Please use the links below and/or update your bookmarks.=
==Anaplastic large cell lymphoma (ALCL)==
==Cutaneous T-cell lymphoma (CTCL)==
==Extranodal NK- and T-cell lymphoma, nasal type==
==NK- and T-cell lymphoma==
==Peripheral T-cell Lymphoma (PTCL)==
Category:Obsolete pages
TACE

Transarterial chemoembolization (TACE) refers to a number of local delivery approaches which are almost exclusively used in the treatment of hepatocellular carcinoma or hepatic metastases. Typically there is an inert lipid-based carrier such as lipiodol and an expander such as gelatin foam, along with chemotherapy. Another formulation consists of drug-eluting beads.
Examples chemotherapies include (this list will be filled in over time):
*Cisplatin, Doxorubicin, Epirubicin, and Mitomycin
*Doxorubicin
Category:Locally delivered therapies
Category:Hepatocellular carcinoma medications
Category:Uveal melanoma medications